Identity
- Security key
- 13181
- Ticker
- CCCC
- Type
- CS — Common Stock
- Exchange
- Nasdaq(XNAS)
- Venue group
- NASDAQ
- Operating MIC
- XNAS
- Market
- stocks
- Locale
- us
- Currency
- USD
- Listed
- 2020-10-02
- Round lot
- 100
- Active
- Yes
- Last seen in a load
- 2026-08-14 20:49
- Vendor updated
- 2026-08-13 06:09
- Ticker root / suffix
- CCCC
Detail
Enriched 2026-08-14 20:47
- Market cap
- $479,798,030.4
- Shares outstanding (class)
- 110,567,222
- Shares outstanding (weighted)
- 123,025,136
- SIC
- 2836 BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Employees
- 104
- Location
- WATERTOWN, MA
- Homepage
- https://www.c4therapeutics.com
- Description
C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.